Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745447 | 1.00 | PLD1 (0.60) | PLD1PRKCQPRKCDHDAC1ALDH1A1 | |
| SCHEMBL2244221 | 1.00 | PLD1 (0.60) | PLD1PRKCQPRKCDHDAC1ALDH1A1 | |
| SCHEMBL709716 | 1.00 | PLD1 (0.60) | PLD1PRKCQPRKCDHDAC1ALDH1A1 | |
| Bromide SCHEMBL4002506 | 0.98 | PLD1 (0.58) | PLD1PRKCQPRKCDHDAC1ALDH1A1 | |
| Bromide SCHEMBL4002504 | 0.98 | PLD1 (0.58) | PLD1PRKCQPRKCDHDAC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31046391 | 0.98 | PLD1 (0.58) | PLD1PRKCQPRKCDHDAC1ALDH1A1 | |
| SCHEMBL30146642 | 0.86 | PRKCQ (0.47) | PLD1PRKCQPRKCDHDAC1ACVR1 | |
| SCHEMBL1127392 | 0.83 | PLD1 (0.58) | PLD1ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL7801440 | 0.83 | PLD1 (0.58) | PLD1ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL13149760 | 0.81 | PLD1 (0.51) | PLD1HDAC1ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| CN-110167926-A | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | 米托布里奇公司 | 2019-08-23 | — | — | CN | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2809669-B1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| EP-2809669-B1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-07-01 | — | — | US | disclosed |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-06-10 | — | — | US | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| EP-1373220-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003076431-A1 | BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2003-08-28 | — | — | US | disclosed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002088093-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | PLD1 1276/4885PRKCQ 3869/4885PRKCD 4103/4885 |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | PLD1 1237/4885PRKCQ 201/4885PRKCD 380/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | PLD1 1276/4885PRKCQ 3869/4885PRKCD 4103/4885 |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | PLD1 1846/4885PRKCQ 3946/4885PRKCD 4027/4885 |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | PLD1 1846/4885PRKCQ 3946/4885PRKCD 4027/4885 |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | PLD1 1846/4885PRKCQ 3946/4885PRKCD 4027/4885 |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | PLD1 1846/4885PRKCQ 3946/4885PRKCD 4027/4885 |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | PLD1 1237/4885PRKCQ 201/4885PRKCD 380/4885 |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | PLD1 1846/4885PRKCQ 3946/4885PRKCD 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.